218 related articles for article (PubMed ID: 21855111)
1. Expression of the Ets transcription factor EHF in serous ovarian carcinoma effusions is a marker of poor survival.
Brenne K; Nymoen DA; Hetland TE; Trope' CG; Davidson B
Hum Pathol; 2012 Apr; 43(4):496-505. PubMed ID: 21855111
[TBL] [Abstract][Full Text] [Related]
2. Ets-1 mRNA expression in effusions of serous ovarian carcinoma patients is a marker of poor outcome.
Davidson B; Risberg B; Goldberg I; Nesland JM; Berner A; Tropé CG; Kristensen GB; Bryne M; Reich R
Am J Surg Pathol; 2001 Dec; 25(12):1493-500. PubMed ID: 11717538
[TBL] [Abstract][Full Text] [Related]
3. Rab25 is overexpressed in Müllerian serous carcinoma compared to malignant mesothelioma.
Brusegard K; Stavnes HT; Nymoen DA; Flatmark K; Trope CG; Davidson B
Virchows Arch; 2012 Feb; 460(2):193-202. PubMed ID: 22249560
[TBL] [Abstract][Full Text] [Related]
4. Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma.
Elloul S; Elstrand MB; Nesland JM; Tropé CG; Kvalheim G; Goldberg I; Reich R; Davidson B
Cancer; 2005 Apr; 103(8):1631-43. PubMed ID: 15742334
[TBL] [Abstract][Full Text] [Related]
5. CIAPIN1 and ABCA13 are markers of poor survival in metastatic ovarian serous carcinoma.
Nymoen DA; Holth A; Hetland Falkenthal TE; Tropé CG; Davidson B
Mol Cancer; 2015 Feb; 14():44. PubMed ID: 25889687
[TBL] [Abstract][Full Text] [Related]
6. Defining a prognostic marker panel for patients with ovarian serous carcinoma effusion.
Davidson B; Smith Y; Nesland JM; Kærn J; Reich R; Tropè CG
Hum Pathol; 2013 Nov; 44(11):2449-60. PubMed ID: 24011953
[TBL] [Abstract][Full Text] [Related]
7. Expression of the chromatin remodeling factor Rsf-1 is upregulated in ovarian carcinoma effusions and predicts poor survival.
Davidson B; Trope' CG; Wang TL; Shih IeM
Gynecol Oncol; 2006 Dec; 103(3):814-9. PubMed ID: 16844205
[TBL] [Abstract][Full Text] [Related]
8. MUC4 is upregulated in ovarian carcinoma effusions and differentiates carcinoma cells from mesothelial cells.
Davidson B; Baekelandt M; Shih IeM
Diagn Cytopathol; 2007 Dec; 35(12):756-60. PubMed ID: 18008338
[TBL] [Abstract][Full Text] [Related]
9. Proton magnetic resonance metabolomic characterization of ovarian serous carcinoma effusions: chemotherapy-related effects and comparison with malignant mesothelioma and breast carcinoma.
Vettukattil R; Hetland TE; Flørenes VA; Kærn J; Davidson B; Bathen TF
Hum Pathol; 2013 Sep; 44(9):1859-66. PubMed ID: 23656974
[TBL] [Abstract][Full Text] [Related]
10. HUR mRNA expression in ovarian high-grade serous carcinoma effusions is associated with poor survival.
Davidson B; Holth A; Hellesylt E; Hadar R; Katz B; Tropé CG; Reich R
Hum Pathol; 2016 Feb; 48():95-101. PubMed ID: 26640230
[TBL] [Abstract][Full Text] [Related]
11. HOXB8 expression in ovarian serous carcinoma effusions is associated with shorter survival.
Stavnes HT; Holth A; Don T; Kærn J; Vaksman O; Reich R; Trope' CG; Davidson B
Gynecol Oncol; 2013 May; 129(2):358-63. PubMed ID: 23438671
[TBL] [Abstract][Full Text] [Related]
12. Expression of palladin is associated with disease progression in metastatic high-grade serous carcinoma.
Davidson B; Bock AJ; Holth A; Nymoen DA
Cytopathology; 2020 Nov; 31(6):572-578. PubMed ID: 32741023
[TBL] [Abstract][Full Text] [Related]
13. Argonaute, Dicer, and Drosha are up-regulated along tumor progression in serous ovarian carcinoma.
Vaksman O; Hetland TE; Trope' CG; Reich R; Davidson B
Hum Pathol; 2012 Nov; 43(11):2062-9. PubMed ID: 22647351
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic and prognostic role of the insulin growth factor pathway members insulin-like growth factor-II and insulin-like growth factor binding protein-3 in serous effusions.
Slipicevic A; Øy GF; Askildt IC; Holth A; Hellesylt E; Flørenes VA; Davidson B
Hum Pathol; 2009 Apr; 40(4):527-37. PubMed ID: 19121847
[TBL] [Abstract][Full Text] [Related]
15. Death domain-associated protein (DAXX) expression is associated with poor survival in metastatic high-grade serous carcinoma.
Davidson B; McFadden E; Holth A; Brunetti M; Flørenes VA
Virchows Arch; 2020 Dec; 477(6):857-864. PubMed ID: 32533344
[TBL] [Abstract][Full Text] [Related]
16. Soluble AXL is ubiquitously present in malignant serous effusions.
Flem Karlsen K; McFadden E; Flørenes VA; Davidson B
Gynecol Oncol; 2019 Feb; 152(2):408-415. PubMed ID: 30448261
[TBL] [Abstract][Full Text] [Related]
17. Wee1 is a novel independent prognostic marker of poor survival in post-chemotherapy ovarian carcinoma effusions.
Slipicevic A; Holth A; Hellesylt E; Tropé CG; Davidson B; Flørenes VA
Gynecol Oncol; 2014 Oct; 135(1):118-24. PubMed ID: 25093290
[TBL] [Abstract][Full Text] [Related]
18. TSAP6 is a novel candidate marker of poor survival in metastatic high-grade serous carcinoma.
Broner EC; Tropé CG; Reich R; Davidson B
Hum Pathol; 2017 Feb; 60():180-187. PubMed ID: 27825812
[TBL] [Abstract][Full Text] [Related]
19. Expression levels of the nerve growth factor receptors TrkA and p75 in effusions and solid tumors of serous ovarian carcinoma patients.
Davidson B; Lazarovici P; Ezersky A; Nesland JM; Berner A; Risberg B; Tropé CG; Kristensen GB; Goscinski M; van de Putte G; Reich R
Clin Cancer Res; 2001 Nov; 7(11):3457-64. PubMed ID: 11705863
[TBL] [Abstract][Full Text] [Related]
20. The clinical role of phospholipase A2 isoforms in advanced-stage ovarian carcinoma.
Gorovetz M; Baekelandt M; Berner A; Trope' CG; Davidson B; Reich R
Gynecol Oncol; 2006 Dec; 103(3):831-40. PubMed ID: 16919315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]